Atara Biotherapeutics, Inc.
tabelecleucel
EBV+ PTLD
Resolved
61days ago
Advisory committee · May 7, 2026
What's at stake
An FDA advisory committee reviews tabelecleucel for EBV+ PTLD around May 7, 2026. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“On May 7, 2026, Atara Biotherapeutics, Inc. (the “Company”) issued a press release titled “Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel” providing an update following the Type A meeting with the U.S. Food and Drug Admin”